Navirel (Vinorelbine)

Vinorelbine binds to tubulin proteins, preventing microtubule assembly needed for mitotic spindle formation. This blocks cells in the M phase of the cell cycle, leading to apoptosis of rapidly dividing cancer cells while having limited effect on non‑dividing normal cells.

The exact dose of Navirel is determined by the prescribing physician based on the patient’s body surface area, disease stage, prior therapies and overall health. Dosing is individualized and delivered by a qualified healthcare professional via intravenous infusion.

Vinorelbine is classified as contraindicated during pregnancy because it may cause fetal harm. Limited data exist for breastfeeding, and the drug is expected to be excreted in milk, so nursing mothers are advised not to breastfeed while receiving treatment.

To request Navirel, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Vinorelbine belongs to the Vinca alkaloid class, similar to vincristine and vinblastine. Compared with taxanes such as paclitaxel, vinorelbine has a distinct toxicity profile, with more pronounced neutropenia but less neuropathy. Choice of agent depends on tumour type, prior therapy and patient tolerance.

Navirel should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vials in their original packaging until use and discard any product that has been exposed to temperatures outside the recommended range.

Navirel is given by intravenous infusion, typically over 6–10 minutes, under the supervision of a qualified healthcare professional. The infusion rate and schedule are set by the treating oncologist according to the prescribed regimen.

The most critical risks include severe neutropenia leading to infection, febrile neutropenia, pulmonary toxicity such as interstitial pneumonitis, and hypersensitivity reactions that may present as rash, bronchospasm or anaphylaxis. Prompt medical attention is required if any of these occur.

Navirel is contraindicated in patients with known hypersensitivity to vinorelbine or other Vinca alkaloids, those with severe bone‑marrow suppression, uncontrolled infections, and pregnant or nursing women. Caution is also advised for patients with significant hepatic impairment or pre‑existing cardiac disease.